Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
about
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines.A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and MaImmunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infantsMeningococcal glycoconjugate vaccines.Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) induces memory B cell responses in healthy Kenyan toddlers.A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administAntibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal ConInteractions of conjugate vaccines and co-administered vaccinesSafety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children.Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.Antibody persistence and immunologic memory in children vaccinated with 4 doses of pneumococcal conjugate vaccines: Results from 2 long-term follow-up studies.Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults.The history of pneumococcal conjugate vaccine development: dose selection.Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, contrPneumococcal conjugated vaccine: PHiD-CV.27th Annual Meeting of the European Society for Pediatric Infectious Disease.DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™): a guide to its use in infants.Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.6th World Congress of the World Society for Pediatric Infectious Diseases (WSPID)
P2860
Q33909172-F014C033-226F-4879-8CE9-B117E70B1CD4Q34082225-81AB72CD-5D14-4261-8C58-7820B9FF0F72Q34170021-DB52ABEF-63DC-49DD-9163-63B64461EC69Q34738780-CB51B811-DFD6-41A8-8777-337385CDC17BQ34867264-CA9EA202-8442-4185-BD9A-9F5053268297Q34981631-13B33AC1-ED60-49A1-87DA-20243B1C5C4FQ35194824-D6C0B760-A853-4111-A396-C0FE5840F2D9Q35867061-759967FD-367E-4F1A-895A-085DF10DCF6BQ35887689-7F212377-65A9-464D-A0AB-E8D5F47494C4Q35893171-7BFA9D55-7D59-489A-A828-0D01546A9083Q36184400-809B8470-1082-436D-9AD8-265DAA8BF9FDQ37067275-13BEB287-9A8F-4A28-AD76-3BFEA37D6567Q37130164-5F7894D2-7628-4E4D-ADE4-E757C378C6B0Q37384762-3FDCB28D-6FC0-47D8-907B-D627160AF91AQ37499448-BDEECD8C-3803-474D-967C-6494D98ABD57Q37622887-642C0B5B-A31A-4291-BC58-0E81850BD92EQ37713768-7A258454-95AC-4932-995B-330F8504DE20Q37951530-0A678D9C-337F-4AD6-860F-7B4896E62C8FQ37954709-79AB9783-1443-411F-A717-6806F7E3D76BQ38160248-24D5C1E5-ED3D-4456-B0C4-9C6C5BF0B0E7Q38367830-5299D4B0-F484-4E8E-9E2E-002B84CA5B29Q38631381-CF4AC349-A12F-43FD-A0CD-E0F4672F5651Q40285504-A364C990-74AC-4661-ACC3-F631352667CFQ42638322-480E5042-6C0B-4753-92D1-F84F871BD543Q43777687-9DAA4CDD-BB2C-4343-BDCE-F9B5172707E2Q46008302-24B67DDC-43AC-41EC-BBB5-9CFDA4ACF18FQ54416744-090D635B-7FBD-4D16-BB8A-C7D293D3720DQ57108439-A72D3E53-AC19-44B6-963D-D8A68B6B9B11
P2860
Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunogenicity of routinely us ...... D conjugate vaccine (PHiD-CV).
@en
Immunogenicity of routinely us ...... ae protein D conjugate vaccine
@nl
type
label
Immunogenicity of routinely us ...... D conjugate vaccine (PHiD-CV).
@en
Immunogenicity of routinely us ...... ae protein D conjugate vaccine
@nl
prefLabel
Immunogenicity of routinely us ...... D conjugate vaccine (PHiD-CV).
@en
Immunogenicity of routinely us ...... ae protein D conjugate vaccine
@nl
P2093
P1476
Immunogenicity of routinely us ...... D conjugate vaccine (PHiD-CV).
@en
P2093
Christian Petit
Ilse Dieussaert
Laurence Bernard
Leszek Szenborn
Lode Schuerman
Markus Knuf
Masnuel Moro
Nancy Bermal
P304
P356
10.1097/INF.0B013E318199F61B
P433
P577
2009-04-01T00:00:00Z